Skip to main content


We're creating a new version of this page. See preview

  • Oral presentation
  • Open Access

Foxp3 expression in breast cancer patient from Qatar: survival analysis

  • 1, 2,
  • 1,
  • 1,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2 and
  • 1
Journal for ImmunoTherapy of Cancer20153 (Suppl 1) :O2

  • Published:


  • Breast Cancer
  • Breast Cancer Patient
  • Survival Analysis
  • Hormone Receptor
  • Tumor Microenvironment

In breast cancer, the presence of Foxp3 (Tregs) [1] within the tumor milieu has been a matter of debate. Some studies have determined that infiltration of Tregs was associated with poor survival, while others revealed no impact on survival, however this depends on their type, type of cells expressing Foxp3 and the density of the Tregs population [2].

The goal of our study was to quantify Foxp3 in breast cancer patients from Qatar and correlate with their survival.


Expression of FoxP3 was studied in 132 FFPE samples with known clinico-pathological data by immunohistochemistry technique and quantified by modified H-score system by pathologist. Results were analyzed via SPSS.


Analysis was carried for 132 patients. Age at time of diagnosis was 49 ±10.4 years. 76.2% of the patients showed positive expression of FoxP3. FoxP3 expression was not correlated with patient age or hormone receptors. Expression of Foxp3 positively correlate with better patient survival when compared to negative expression (94.1, 95% CI 85.6 - 102.6 versus 83.6, 95% CI 71.8 - 95.5, p 0.60).


FoxP3 is expressed on lymphocytes that are present in the tumor microenvironment regardless of breast cancer subtypes. Foxp3 is correlated with better survival.

Authors’ Affiliations

Research, Weill Cornell Medical College in Qatar, Doha, Qatar
Hamad Medical Corporation, Doha, Qatar


  1. Mackay C.R.: Dual personality of memory T cells. Nature. 1999, 401 (6754): 659-660. 10.1038/44309.View ArticlePubMedGoogle Scholar
  2. Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Lee A.H., Ellis I.O., Green A.R.: An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Research and Treatment. 2011b, 127 (1): 99-108. 10.1007/s10549-010-0987-8.View ArticleGoogle Scholar


© Mohamed et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.